Skip Navigation

Annals of Oncology 2004 15(9):1444; doi:10.1093/annonc/mdh358
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Ross, G. A.
Right arrow Articles by Kettels, J. A.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Ross, G. A.
Right arrow Articles by Kettels, J. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2004 European Society for Medical Oncology

Reply to the Letter to the Editor on "Topotecan versus paclitaxel in second-line therapy: a lost opportunity for quality-of-life evaluation?", by G. Apolone & A. Buda (Ann Oncol 2004; 15: 1443–1444)

The first 10% of the full text of this article appears below.

Apolone and Buda have provided very thoughtful observations regarding our statements on quality of life (QoL) in our update on the long-term outcomes in patients with advanced epithelial ovarian cancer. They rightly point out several issues that are endemic to most . . . [Full Text of this Article]

G. A. Ross* and J. A. Kettels

GlaxoSmithKline, New Frontiers Science Park, Third Avenue, Harlow CM19 5AW, Essex, UK

* Email: graham.a.ross@gsk.com


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?